- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
Setting: Primary care
The first level of healthcare, including general medical services, such as family medicine
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Primary care
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Community
- Primary care
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- Community
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Influenza
- Avian Influenza
- Pharmacological intervention
- Nitric Oxide Nasal Spray
- Adults (18-64 years)
- Hospital
- Primary care
- Non-hospital health centre
- Emergency department
- Long-term care facility
- SARS-CoV-2
- Post-COVID-19
- Blood sample
- Nasopharyngeal swab
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Outpatient clinic
- Community
- Primary care
- Non-hospital health centre
- Emergency department
- SARS-CoV-2
- Post-COVID-19
- Acute COVID-19
- Adults (18-64 years)
- Hospital
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Acute COVID-19
- Blood sample
- Nasopharyngeal swab
- PBMC
- Serum
- Stool sample
- Whole blood
- Plasma
- Adults (18-64 years)
- Hospital
- Primary care
- SARS-CoV-2
- Influenza virus
- Acute COVID-19
- Influenza
- Blood sample
- PBMC
- Serum
- Whole blood
- Plasma
- Adults (18-64 years)
- General population
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Primary care
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immunomodulator
- Prednisolone
- Vitamin B1
- Vitamin B12
- Vitamin B6